EUVIMEDSkopri EUVIMED
Systematische ÜbersichtNetzwerk-Metaanalyse

Association Between GLP‐1 Receptor Agonists and the Risk of Colon Cancer in Adults With Type 2 Diabetes or Obesity: A Systematic Review and Network Meta‐Analysis

Man Guo iD, Yong Liu, Yan Zeng iD, Jiao Chen iD, Chen Zeng, Lin-Lin Huang, Ji-Ying Wang, Yang-Hao-Tian Wu, Qi Wu, Fang-Yuan Teng iD, Yong Xu iD

Diabetes/Metabolism Research and Reviews · 2026

DOI: 10.1002/dmrr.70134 ↗

At a glance

Systematische Übersicht in Diabetes/Metabolism Research and Reviews, 2026. Written by Man Guo and 10 co-authors. Institution: Department of Endocrinology and Metabolism, The Affiliated Hospital of Southwest Medical University, and Metabolic Vascular Disease Key Laboratory of…. Major MEDLINE topics: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Colonic Neoplasms, Obesity. 57 references. Funded by: Natural Science Foundation of China, Sichuan Province Science and Technology Support Program, Luzhou Science and Technology Program.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background and Objective To evaluate the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and intestinal cancers and to explore the risk factors for these associations.

Methods

PubMed, Embase, Web of Science, Scopus, Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov were searched through 13 June 2024, to identify randomised clinical trials (RCTs) assessing the relationship between GLP‐1 RA use and colorectal, colon, rectal, and intestinal cancers. Pooled relative risks (RRs) and 95% confidence intervals (CIs) for each outcome were calculated.

Results

In 17 RCTs comprising 36,415 patients, GLP‐1 RAs was associated with a significantly reduced risk of colon cancer (RR, 0.34; 95% CI, 0.17–0.68; I 2 = 0.0%), and showed a neutral effect on the risk of colorectal carcinoma, rectal, and intestinal cancer, with RRs of 1.13 (95% CI, 0.92–1.39; I 2 = 0.0%), 3.64 (95% CI, 0.76–17.40; I 2 = 0.0%), and 0.76 (95% CI, 0.31–1.84; I 2 = 23.3%), respectively. In the network meta‐analysis and subgroup analysis, a potential association was observed between albiglutide and subcutaneous semaglutide and a lower incidence of colon cancer among adults treated for a longer duration and with lower baseline HbA1c levels, regardless of baseline body mass index, age, or type of control group.

Conclusions

GLP‐1 RAs may be associated with a lower risk of colon cancer in adults with type 2 diabetes mellitus, warranting further validation in trials among high‐risk populations. Trial Registration The study protocol was pre‐registered and published on PROSPERO (CRD: 42024548010; https://www.crd.york.ac.uk/prospero/#recordDetails )

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsColonic NeoplasmsObesityHypoglycemic AgentsHumansRisk FactorsSemaglutide

Author keywords

colon cancerdiabetesglucagon‐like peptide‐1 receptor agonistmeta‐analysisobesitysemaglutide

Substances

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsSemaglutide

Authors and institutions

  • Department of Endocrinology and Metabolism, The Affiliated Hospital of Southwest Medical University, and Metabolic Vascular Disease Key Laboratory of Sichuan Province, and Sichuan-Chongqing Joint Key Laboratory of Metab…
  • Department of Intensive Care Unit, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
  • Department of Intensive Care Unit, Wangcang People's Hospital, Guangyuan, China.
  • Department of Endocrinology, Sichuan Mental Health Center, The Third Hospital of Mianyang, Mianyang, China.
  • School of Public Health, Chongqing Medical University, Chongqing, China.
  • Department of Pathology, The Affiliated Hospital of Southwest Medical University, and Luzhou Key Laboratory of Precision Pathology Diagnosis for Serious Diseases, Luzhou, China.

ORCID profiles: Man Guo, Yan Zeng, Jiao Chen, Fang-Yuan Teng, Yong Xu

Funding

  • Natural Science Foundation of China
  • Sichuan Province Science and Technology Support Program
  • Luzhou Science and Technology Program
  • Scientific Research Projects of Southwest Medical University
  • National Natural Science Foundation of China

Cite

APA

Guo, M., Liu, Y., Zeng, Y., Chen, J., Zeng, C., Huang, L. L., Wang, J. Y., Wu, Y. H., Wu, Q., Teng, F. Y., & Xu, Y. (2026). Association Between GLP‐1 Receptor Agonists and the Risk of Colon Cancer in Adults With Type 2 Diabetes or Obesity: A Systematic Review and Network Meta‐Analysis. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.70134

Vancouver

Guo M, Liu Y, Zeng Y, Chen J, Zeng C, Huang LL, et al. Association Between GLP‐1 Receptor Agonists and the Risk of Colon Cancer in Adults With Type 2 Diabetes or Obesity: A Systematic Review and Network Meta‐Analysis. Diabetes/Metabolism Research and Reviews. 2026. doi:10.1002/dmrr.70134

BibTeX
@article{Guo2026,
  author = {Guo, Man and Liu, Yong and Zeng, Yan and Chen, Jiao and Zeng, Chen and Huang, Lin-Lin and Wang, Ji-Ying and Wu, Yang-Hao-Tian and Wu, Qi and Teng, Fang-Yuan and Xu, Yong},
  title = {Association Between GLP‐1 Receptor Agonists and the Risk of Colon Cancer in Adults With Type 2 Diabetes or Obesity: A Systematic Review and Network Meta‐Analysis},
  journal = {Diabetes/Metabolism Research and Reviews},
  year = {2026},
  doi = {10.1002/dmrr.70134}
}
Start for free →